The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
144
Collaborative Neuroscience Network - CNS
Los Alamitos, California, United States
RECRUITINGICON Early Phase Services
San Antonio, Texas, United States
RECRUITINGLilly Centre for Clinical Pharmacology
Singapore, Singapore
RECRUITINGNumber of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Postdose to Approximately Week 27
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY4064912
PK: AUC of LY4064912
Time frame: Predose Up to Day 78
PK: Maximum Concentration (Cmax) of LY4064912
PK: Cmax of LY4064912
Time frame: Predose Up to Day 78
Change from Baseline in Body Weight
Change from Baseline in Body Weight
Time frame: Baseline to Approximately Week 27
Effects of LY4064912 on Renal Hemodynamics and Renal Function
Glomerular Filtration Rate (GFR)
Time frame: Baseline Up to Day 31
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Administered IV